Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 7/20 | 0.56 |
| ▸ | ACE | P12821 | 5/20 | 0.56 |
| ▸ | CPA1 | P15085 | 2/20 | 0.56 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | FCER2 | P06734 | 2/20 | 0.52 |
| ▸ | MC5R | P33032 | 2/20 | 0.51 |
| ▸ | MC1R | Q01726 | 2/20 | 0.51 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
| ▸ | ALB | P02768 | 1/20 | 0.48 |
| ▸ | IL2 | P60568 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1060389 | 1.00 | MME (0.56) | MMEACECPA1ACE2CA2 | |
| SCHEMBL1097466 | 0.95 | MME (0.57) | MMEACECPA1ACE2CA2 | |
| SCHEMBL11241144 | 0.94 | MME (0.56) | MMEACECPA1ACE2CA2 | |
| SCHEMBL7932520 | 0.89 | MC1R (0.64) | MMEACECPA1ACE2CA2 | |
| Hydrochloric Acid SCHEMBL8449735 | 0.88 | MME (0.57) | MMEACECPA1ACE2MMP2 | |
| SCHEMBL27650809 | 0.86 | SIGMAR1 (0.54) | MMEACECPA1ACE2CA2 | |
| SCHEMBL2008563 | 0.86 | SIGMAR1 (0.54) | MMEACECPA1ACE2CA2 | |
| SCHEMBL18435514 | 0.85 | MME (0.62) | MMEACECPA1ACE2CA2 | |
| SCHEMBL839945 | 0.85 | MME (0.62) | MMEACECPA1ACE2CA2 | |
| SCHEMBL7889581 | 0.85 | MME (0.62) | MMEACECPA1ACE2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807678-B2 | Peptidomimetics of biologically active metallopeptides | PALATIN TECHNOLOGIES, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-7718802-B2 | Agonist or antgonist and binders and inversion of agonist; use in the treatment of metabolic, immune, infection-related and melanocortin receptor mediated disorders | PALATIN TECHNOLOGIES, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-7655658-B2 | Use of in the treatment of melanocortin receptor-associated disorders such as in treatment of anorexia, as a weight gain aid, for treatment of obesity | PALATIN TECHNOLOGIES, INC. (US) | 2010-02-02 | — | — | US | disclosed |
| WO-2009144432-A1 | MC4-R AGONISTS FOR THE TREATMENT OF OBESITY | PALATIN TECHNOLOGIES, INC. (US) | 2009-12-03 | — | — | WO | disclosed |
| US-7550602-B1 | Small molecule compositions for sexual dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-7456184-B2 | Melanocortin receptor-specific compounds | PALATIN TECHNOLOGIES INC. (US) | 2008-11-25 | — | — | US | disclosed |
| EP-1622618-A4 | MELANOCORTIN RECEPTOR-SPECIFIC COMPOUNDS | PALATIN TECHNOLOGIES INC (US) | 2008-08-27 | — | — | EP | disclosed |
| US-7417027-B2 | Linear and cyclic melanocortin receptor-specific peptides | PALATIN TECHNOLOGIES, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| US-7326707-B2 | Bicyclic melanocortin-specific compounds | PALATIN TECHNOLOGIES INCORPORATED (US) | 2008-02-05 | — | — | US | disclosed |
| US-7307063-B2 | Melanocortin metallopeptides for treatment of sexual dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2007-12-11 | — | — | US | disclosed |
| WO-2005079574-A1 | BICYCLIC MELANOCORIN-SPECIFIC COMPOUNDS | PALATIN TECHNOLOGIES, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| US-20050176728-A1 | Agonist or antgonist and binders and inversion of agonist; use in the treatment of metabolic, immune, infection-related and melanocortin receptor mediated disorders | PALATIN TECHNOLOGIES, INC. (US) | 2005-08-11 | — | — | US | disclosed |
| EP-1208377-A4 | MELANOCORTIN METALLOPEPTIDE CONSTRUCTS, COMBINATORIAL LIBRARIES AND APPLICATIONS | PALATIN TECHNOLOGIES INC (US) | 2005-04-20 | — | — | EP | disclosed |
| US-20050038230-A1 | Linear and cyclic melanocortin receptor-specific peptides | PALATIN TECHNOLOGIES, INC. (US) | 2005-02-17 | — | — | US | disclosed |
| WO-2004098602-A1 | MELANOCORTIN RECEPTOR-SPECIFIC COMPOUNDS | PALATIN TECHNOLOGIES, INC. (US) | 2004-11-18 | — | — | WO | disclosed |
| EP-1441750-A2 | LINEAR AND CYCLIC MELANOCORTIN RECEPTOR-SPECIFIC PEPTIDES | Palatin Technologies, Inc. (US) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003006620-A2 | LINEAR AND CYCLIC MELANOCORTIN RECEPTOR-SPECIFIC PEPTIDES | PALATIN TECHNOLOGIES, INC. (US) | 2003-01-23 | — | — | WO | disclosed |
| WO-2002064091-A2 | MELANOCORTIN METALLOPEPTIDES FOR TREATMENT OF SEXUAL DYSFUNCTION | PALATIN TECHNOLOGIES, INC. (US) | 2002-08-22 | — | — | WO | disclosed |
| EP-1208377-A1 | MELANOCORTIN METALLOPEPTIDE CONSTRUCTS, COMBINATORIAL LIBRARIES AND APPLICATIONS | Palatin Technologies, Inc. (US) | 2002-05-29 | — | — | EP | disclosed |
| WO-2001013112-A1 | MELANOCORTIN METALLOPEPTIDE CONSTRUCTS, COMBINATORIAL LIBRARIES AND APPLICATIONS | PALATIN TECHNOLOGIES, INC. (US) | 2001-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176728-A1 | Agonist or antgonist and binders and inversion of agonist; use in the treatment of metabolic, immune, infection-related and melanocortin receptor mediated disorders | MC3R, MC4R, MC1R | MME 2714/4885ACE 2701/4885CPA1 2899/4885 |
| US-20050038230-A1 | Linear and cyclic melanocortin receptor-specific peptides | MC1R, MC3R, MC5R | MME 305/4885ACE 2267/4885CPA1 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.